Chardan analyst Geulah Livshits lowered the firm’s price target on Metagenomi (MGX) to $7 from $11 and keeps a Buy rating on the shares after the company reported Q3 results, announced the appointment of Dr. Jian Irish to CEO, and shared updated preclinical data on lead in vivo insertion program MGX-001 in hemophilia A. The firm updated its model for Q3 financials and removed the majority of platform value from the model in light of prioritization.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
- Metagenomi Announces Positive Preclinical Data for MGX-001
- Metagenomi CEO Brian Thomas to transition out of role, Jian Irish to succeed
- Metagenomi reports Q3 EPS (55c), consensus (53c)
- Metagenomi reports new dose range finding data from MGX-001 hemophilia A program
- Metagenomi reduces workforce by 25%